The top Democratic recipients of Big Pharma cash in Congress are echoing industry talking points in opposition to a push to suspend key intellectual property protections.
The top Democratic recipients of Big Pharma cash in Congress are echoing industry talking points in opposition to a push to suspend key intellectual property protections.